Ocular Therapeutix Expands Its Board of Directors with the Appointment of Renowned Retinal Specialist Jeffrey S. Heier, M.D.

BEDFORD, Mass.--()--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Jeffrey S. Heier, M.D., a prominent retinal specialist, has been elected to Ocular’s Board of Directors. Dr. Heier is a leading retinal clinical researcher of new treatments for diseases of the back of the eye, including macular degeneration, diabetic macular edema, and venous occlusive disease.

“We are very excited to have Dr. Heier join the Board of Directors as we continue to advance our hydrogel platform technology and product programs addressing diseases of both the front and back of the eye. Jeff is a highly regarded retinal specialist and has been involved with numerous programs for back of the eye diseases. His background complements fellow Board member Dr. Richard Lindstrom’s expertise in front of the eye diseases. We expect Jeff’s expertise to be valuable as we further progress our anti-VEGF and TKI programs toward the clinic,” said Amar Sawhney, Ph.D., President and Chief Executive Officer.

Dr. Heier currently serves as the Director of the Vitreoretinal Service and Retina Research at Ophthalmic Consultants of Boston (OCB), one of the premier multi-specialty ophthalmology practices in the United States. He is also the Co-Director of the Vitreoretinal Fellowship at OCB/Tufts University School of Medicine. Further, Dr. Heier is the President-elect of the New England Ophthalmological Society and is on the Executive Board of the Retina Society and the Board of the American Society of Retina Specialists. He is the former Secretary of Online Education for the American Academy of Ophthalmology and the prior President of the Center for Eye Research and Education Foundation (Boston). Dr. Heier is on the Scientific Advisory Board or serves as Clinical Design Consultant to a number of biotechnical or pharmaceutical companies and has been the lead investigator on numerous clinical trials, ranging from phase I safety and proof of concept trials to phase IV post-marketing studies. These advisory roles have involved many companies working on anti-VEGF agents for the treatment of wet AMD and other retinal diseases. He has received numerous awards and has been the author or co-author on more than 80 peer-reviewed articles or books and book chapters.

Dr. Heier received his medical degree from Boston University and completed his ophthalmology residency at Fitzsimons Army Medical Center. He also completed a vitreoretinal fellowship at OCB/Tufts University School of Medicine.

Dr. Heier stated, “This is an exciting time for Ocular Therapeutix as it anticipates further clinical progress and expects to report key data from clinical studies later this year. I view Ocular’s technology as a very promising approach to address the deficiencies of current therapies for the treatment of back of the eye diseases, and I look forward to contributing to the preclinical and clinical development efforts to advance these programs.”

About Ocular Therapeutix

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain and allergic conjunctivitis, and Phase 2 clinical development for glaucoma and inflammatory dry eye disease. The Company is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the development of the Company’s product candidates, such as the ongoing development of the Company’s sustained release hydrogel depot technology, the advancement of the Company's other product candidates and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend", "goal," "may", "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to the timing and costs involved in commercializing ReSure® Sealant, the initiation and conduct of clinical trials, availability of data from clinical trials and expectations for regulatory submissions and approvals, the Company’s scientific approach and general development progress, the availability or commercial potential of the Company’s product candidates, the sufficiency of cash resources and need for additional financing or other actions and other factors discussed in the “Risk Factors” section contained in the Company’s quarterly and annual reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.


Ocular Therapeutix, Inc.
Brad Smith
Chief Financial Officer
Scott Corning
Vice President of Sales and Marketing
Burns McClellan on behalf of Ocular Therapeutix
Kimberly Minarovich, 212-213-0006
Justin Jackson, 212-213-0006

Recent Stories

RSS feed for Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc.